Journals / Turkish Thoracic Journal / 2018 / Cilt: 19 - Sayı: 1

Evaluation of Treatment Indications, Tuberculin Skin Test, and Bacillus Calmette-Guerin Vaccination Scars in the Cases of Latent Tuberculosis Infection Treatment

Pages
7–12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Inthe group with TST-positive children aged <15 years with one and 2 BCG vaccine scars, the decrease between pre- and post-treatmentTST results showed a statistically significant difference.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVES: The aim of our study was to evaluate the latent tuberculosis infection (LTBI) treatment application and to investigate if thereis change between tuberculin skin test (TST) results according to bacillus Calmette-Guerin (BCG) scar numbers after LTBI treatment withisoniazid (INH).MATERIAL AND METHODS: Data were collected from the LTBI treatment files from the dispensary of 2006.
📊
Key Findings & Data:The results were statisticallyevaluated.RESULTS: Latent tuberculosis infection was administered to 253 cases in 2006.
💡
Conclusion & Impact:Inthe group with TST-positive children aged <15 years with one and 2 BCG vaccine scars, the decrease between pre- and post-treatmentTST results showed a statistically significant difference.
🔬Design:Research Article
📍Scope:2006 Verileri
⚙️Variables:Domain Parameters

Özet

OBJECTIVES: The aim of our study was to evaluate the latent tuberculosis infection (LTBI) treatment application and to investigate if thereis change between tuberculin skin test (TST) results according to bacillus Calmette-Guerin (BCG) scar numbers after LTBI treatment withisoniazid (INH).MATERIAL AND METHODS: Data were collected from the LTBI treatment files from the dispensary of 2006. The results were statisticallyevaluated.RESULTS: Latent tuberculosis infection was administered to 253 cases in 2006. The male/female case rate was 51/49. The age of mostpatients was under 15 years out of 14 cases. The mean age was 8.92±6.87 years (range, 0-84 years). One case had liver function testabnormality and INH was stopped in the first month of treatment. The completion rate of LTBI treatment was 95%. BCG vaccination ratewas 93%. Active tuberculosis did not develop during the LTBI treatment in our study. Of all the cases, 221 scar numbers and TST werefull. Of all cases 221 the scar numbers and TST value were full.TST of the 221 cases according to BCG vaccine scar numbers and indi-cations were compared pre- and post-treatment with INH. Indications for LTBI treatment in these cases were close contact with smear-positive active pulmonary tuberculosis cases (n=77, 35%), TST-positive children aged <15 years (n=138, 62%), and the other (n=6, 3%)immunosuppressed patient cases. After treatment with INH, TST values decreased in the TST-positive children aged <15 years with oneand 2 scars, with a statistically significant this result were found statistically significant (p<0.05).CONCLUSION: The age of patients in most cases with LTBI treatment was under 15 years. The treatment completion rate and BCG vac-cination rate were high. One case had liver function test abnormality. Active tuberculosis did not develop during the LTBI treatment. Inthe group with TST-positive children aged <15 years with one and 2 BCG vaccine scars, the decrease between pre- and post-treatmentTST results showed a statistically significant difference.

🔖

Cite This Article

ÇAKAR, B. (2018). Evaluation of Treatment Indications, Tuberculin Skin Test, and Bacillus Calmette-Guerin Vaccination Scars in the Cases of Latent Tuberculosis Infection Treatment. Turkish Thoracic Journal, Cilt: 19 - Sayı: 1, 7–12. https://ajindex.com/articles/418053

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Nachiappan AC, Rahbar K, Shi X, et al. Pulmonary tuberculosis: role of radiology in diagnosis and management. Radiographics 2017;37:52-72. [CrossRef] Esmail H, Barry CE 3 rd, Young DB, et al. The ongoing chal- lenge of latent tuberculosis. Philos Trans R Soc Lond B Biol Sci 2014;369:20130437. [CrossRef] Silva BC, Grassi MF, Coutinho R, et al. Mycobacterium tubercu- losis epitope-specific interferon-g production in healthy Brazil- ians reactive and non-reactive to tuberculin skin test. Mem Inst Oswaldo Cruz 2014;109:999-1004. [CrossRef] World Health organization. Global tuberculosis report. 2016. Available at: http://who.int/tb/publications/global report/en/ Lalvani A, Pathan AA, Durkan H, et al. Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet 2001;257:2017- 21. [CrossRef] Nienhaus A, Schablon A, Preisser AM, et al. Tuberculosis in healthcare workers - a narrative review from a German perspec- tive. J Occup Med Toxicol 2014;9:9. [CrossRef] Sharma SK, Mohanan S, Sharma A. Relevance of latent TB in- fection in areas of high TB prevalence. Chest 2012;142:761-73. [CrossRef] Ozkara S, Aktas Z, Ozkan S, et al. T.R. Ministry of Health, De- partment of Struggle Against Tuberculosis. Reference Book for the Control of Tuberculosis in Turkey. Rekmay Press, Ankara, pp55 58, 2003.
  2. Yildirim C, Küçük AI, Ongüt G, et al. Evaluation of tuberculin reactivity in different age groups with and without BCG vacci- nation. Mikrobiyol Bul 2009;43:27-35.
  3. Principi N, Esposito S.The present and future of tuberculosis vaccinations. Tuberculosis 2015;95:6-13. [CrossRef] Leung CC, Yew WW, Tam CM, et al. Tuberculin response in BCG vaccinated schoolchildren and the estimation of an- nual risk of infection in Hong Kong. Thorax. 2005;60:124-9. [CrossRef] Menzies D. What does tuberculin reactivity after bac- ille Calmette-Guérin vaccination tell us? Clin Infect Dis 2000;31:S71-4. [CrossRef] Roy A, Eisenhut M, Harris RJ, et al. Effect of BCG vaccina- tion against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. BMJ 2014;349:4643. [CrossRef] Bartalesi F, Vicidomini S, Goletti D, et al. QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J 2009;33:586- 93. [CrossRef] Principi N, Esposito S.The present and future of tuberculosis vaccinations. Tuberculosis 2015;95:6-13. [CrossRef] Gibbs JH, Grang